{
    "root": "4d6581d1-514f-4c40-81d2-05019cf0634d",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ellence",
    "value": "20250324",
    "ingredients": [
        {
            "name": "EPIRUBICIN HYDROCHLORIDE",
            "code": "22966TX7J5"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        }
    ],
    "indications": "ellence indicated component adjuvant therapy patients evidence axillary node tumor involvement following resection primary breast cancer [ ( 14.1 ) ] .",
    "contraindications": "• recommended starting dose ellence 100 120 mg/m 2 . reductions possible given certain combinations ( 2.2 ) . • administer intravenously repeated 3- 4-week cycles , either total dose day 1 cycle divided equally given days 1 8 cycle ( 2.2 ) . • consider antiemetics given conjunction emetigenic drugs ( 2.1 ) . • patients administered 120 mg/m 2 regimen ellence receive prophylactic antibiotic therapy ( 2.1 ) . • adjust first treatment cycle based hematologic nonhematologic toxicities ( 2.3 ) . • reduce dose patients hepatic impairment ( 2.3 , 8.6 ) . • consider lower doses patients severe renal impairment ( 2.3 , 8.7 ) .",
    "warningsAndPrecautions": "ellence available polypropylene single-dose cytosafe® vials containing 2 mg epirubicin hydrochloride per ml sterile , preservative-free , ready-to-use , clear , red solution following strengths : unit sale strength ndc 0009-5091-01 carton 1 single-dose vial 50 mg/25 ml ( 2 mg/ml ) ndc 0009-5093-01 carton 1 single-dose vial 200 mg/100 ml ( 2 mg/ml ) discard unused portion . ellence available onco-tain® glass vials containing 2 mg epirubicin hydrochloride per ml sterile , preservative-free , ready-to-use , clear , red solution following strengths : unit sale strength ndc 0009-5091-25 carton 1 single-dose vial 50 mg/25 ml ( 2 mg/ml ) ndc 0009-5093-10 carton 1 single-dose vial 200 mg/100 ml ( 2 mg/ml ) onco-tain® vial external protection system . discard unused portion .",
    "adverseReactions": "ellence contraindicated patients : •severe myocardial insufficiency [ ( 5.1 ) ] •recent myocardial infarction severe arrhythmias , previous treatment maximum cumulative dose anthracyclines [ ( 5.1 ) ] •severe persistent drug-induced myelosuppression [ ( 5.4 ) ] •severe hepatic impairment ( defined child-pugh class c serum bilirubin level greater 5 mg/dl ) [ ( 5.5 ) ] •severe hypersensitivity ellence , anthracyclines , anthracenediones [ ( 6.1 ) ]",
    "indications_original": "ELLENCE is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see Clinical Studies (14.1)].",
    "contraindications_original": "• The recommended starting dose of ELLENCE is 100 to 120 mg/m 2 . Dosage reductions are possible when given in certain combinations ( 2.2 ). • Administer intravenously in repeated 3- to 4-week cycles, either total dose on Day 1 of each cycle or divided equally and given on Days 1 and 8 of each cycle ( 2.2 ). • Consider use of antiemetics when given in conjunction with other emetigenic drugs ( 2.1 ). • Patients administered the 120 mg/m 2 regimen of ELLENCE should receive prophylactic antibiotic therapy ( 2.1 ). • Adjust dosage after the first treatment cycle based on hematologic and nonhematologic toxicities ( 2.3 ). • Reduce dose in patients with hepatic impairment ( 2.3 , 8.6 ). • Consider lower doses in patients with severe renal impairment ( 2.3 , 8.7 ).",
    "warningsAndPrecautions_original": "ELLENCE is available in polypropylene single-dose CYTOSAFE® vials containing 2 mg epirubicin hydrochloride per mL as a sterile, preservative-free, ready-to-use, clear, red solution in the following strengths:\n                  \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Unit of Sale\n                              \n                           \n                           \n                              \n                                 Strength\n                              \n                           \n                        \n                        \n                           \n                              \n                                 NDC 0009-5091-01\n                              \n                              Carton of 1 Single-dose Vial\n                           \n                           \n                              50 mg/25 mL\n                              (2 mg/mL)\n                           \n                        \n                        \n                           \n                              \n                                 NDC 0009-5093-01\n                              \n                              Carton of 1 Single-dose Vial\n                           \n                           \n                              200 mg/100 mL\n                              (2 mg/mL)\n                           \n                        \n                     \n                  \n                  Discard unused portion.\n                  ELLENCE is available in ONCO-TAIN® glass vials containing 2 mg epirubicin hydrochloride per mL as a sterile, preservative-free, ready-to-use, clear, red solution in the following strengths:\n                  \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Unit of Sale\n                              \n                           \n                           \n                              \n                                 Strength\n                              \n                           \n                        \n                        \n                           \n                              \n                                 NDC 0009-5091-25\n                              \n                              Carton of 1 Single-dose Vial\n                           \n                           \n                              50 mg/25 mL\n                              (2 mg/mL)\n                           \n                        \n                        \n                           \n                              \n                                 NDC 0009-5093-10\n                              \n                              Carton of 1 Single-dose Vial\n                           \n                           \n                              200 mg/100 mL\n                              (2 mg/mL)\n                           \n                        \n                     \n                  \n                  ONCO-TAIN® is the vial external protection system.\n                  Discard unused portion.",
    "adverseReactions_original": "ELLENCE is contraindicated in patients with: \n                  \n                     \n                        •Severe myocardial insufficiency [see Warnings and Precautions (5.1)]\n                     \n                     \n                        •Recent myocardial infarction or severe arrhythmias, or previous treatment with maximum cumulative dose of anthracyclines [see Warnings and Precautions (5.1)]\n                     \n                     \n                        •Severe persistent drug-induced myelosuppression [see Warnings and Precautions (5.4)]\n                     \n                     \n                        •Severe hepatic impairment (defined as Child-Pugh Class C or serum bilirubin level greater than 5 mg/dL) [see Warnings and Precautions (5.5)]\n                     \n                     \n                        •Severe hypersensitivity to ELLENCE, other anthracyclines, or anthracenediones [see Adverse Reactions (6.1)]"
}